Clinical trials
Completed Melanoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,038 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 25 |
| 2001 | 29 |
| 2002 | 25 |
| 2003 | 32 |
| 2004 | 46 |
| 2005 | 50 |
| 2006 | 61 |
| 2007 | 45 |
| 2008 | 40 |
| 2009 | 45 |
| 2010 | 45 |
| 2011 | 46 |
| 2012 | 45 |
| 2013 | 57 |
| 2014 | 42 |
| 2015 | 60 |
| 2016 | 55 |
| 2017 | 43 |
| 2018 | 39 |
| 2019 | 29 |
| 2020 | 28 |
| 2021 | 24 |
| 2022 | 14 |
| 2023 | 15 |
| 2024 | 6 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,038 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 117 |
| Bristol-Myers Squibb | 47 |
| Memorial Sloan Kettering Cancer Center | 45 |
| M.D. Anderson Cancer Center | 40 |
| H. Lee Moffitt Cancer Center and Research Institute | 24 |
| Mayo Clinic | 20 |
| Novartis Pharmaceuticals | 20 |
| Hoffmann-La Roche | 18 |
| GlaxoSmithKline | 14 |
| Pfizer | 14 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Melanoma | 1,038 |
| Neoplasms | 121 |
| Breast Neoplasms | 114 |
| Carcinoma, Non-Small-Cell Lung | 114 |
| Carcinoma, Renal Cell | 103 |
| Neoplasm Metastasis | 92 |
| Skin Neoplasms | 69 |
| Colorectal Neoplasms | 68 |
| Lung Neoplasms | 66 |
| Sarcoma | 63 |
Trials
Showing 1 to 25 of 1,038. Each trial links to its page on Pharma Observatory.
938 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.